Investor's Business Daily on MSN1h
BioNTech Stock Got A IBD RS Rating LiftHow Much Money To Invest Now. Is BioNTech Stock A Buy? BioNTech stock is building a consolidation with a 131.49 buy point.
Zacks.com on MSN5h
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock UpBioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to ...
The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...
BioNTech, the German developer of a widely used mRNA vaccine for the coronavirus, agreed to pay US$800 million (HK$6.24 ...
BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
Frankfurt/Main (dpa) - Mainz bleibt einer Studie zufolge auch im dritten Jahr hintereinander die dynamischste Großstadt in ...
Hinweis: Informationen zur Offenlegungspflicht bei Interessenkonflikten im Sinne von § 85 Abs. 1 WpHG, Art. 20 VO (EU) 596/2014 für das genannte Analysten-Haus ...
Analysten sehen Milliardenpotenzial, rasant steigende Umsätze und ein günstiges KGV. Auch die BioNTech-Aktie profitiert von einer Hochstufung durch renommierte Analysten. Das Kursziel wird deutlich ...
BioNTech is shelling out $800 million upfront to acquire China-based Biotheus in a move that would give it access to a ...
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...
Biontech erweitert seine Pipeline an Krebsmedikamenten mit einem bis zu knapp eine Milliarde Dollar schweren Zukauf. Für die ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback